Visitors to the website will find a rebranded, upgraded online experience that includes a video section that will focus on business developments and commercialization topics. A variety of new content will be added on a regular basis.
Vancouver, British Columbia--(Newsfile Corp. - February 19, 2021) - Izotropic Corporation (CSE: IZO) (OTCQB: IZOZF) (FSE: 1R3) (“Izotropic” or the “Company”), a company commercializing true 3D, dedicated breast CT imaging technology for the earlier detection, diagnosis, and treatment of breast cancers, is pleased to announce it has launched an updated website (www.izocorp.com), which includes an enhanced investor section and a new, comprehensive corporate presentation (https://izocorp.com/investors/presentation/). Visitors to the website will find a rebranded, upgraded online experience that includes a video section that will focus on business developments and commercialization topics. A variety of new content will be added on a regular basis.
Additionally, visitors will find the new corporate presentation details how the company is addressing a significant unmet need in breast imaging with its izoview breast CT platform, an updated commercial development pathway, and a detailed overview of the Company’s workstream activities aimed at increasing time to market.
Izotropic is the only publicly traded company developing a breast CT platform device with plans to provide solutions for breast cancer screening, diagnosis, biopsies, treatment, and monitoring.
CEO Robert Thast stated, “The rebranding and launch of the new website and detailed corporate presentation is the first step in our plans to ramp up awareness for Izotropic in North America and beyond. The recent up-listing to the OTCQB Venture Market has positioned the Company for broader investor visibility in the U.S. We are also preparing marketing programs aimed at increasing visibility with breast cancer advocates, consumers and potential customers in the U.S. medical imaging market. The Company is progressing on every aspect of its business plans and is solidly focussed on expediting patient access to our izoview breast CT system.”
The Company also announces a grant of 300,000 stock options to consultants and 100,000 stock options to management at an exercise price of $1.08. The stock options are in effect for two years and vest immediately.
ON BEHALF OF THE BOARD
For investor relations inquiries contact:
Dan Sammartino
Phone: 1-778-962-0234
Email: IR@izocorp.com
For general inquires contact:
1-833-IZOCORP
info@izocorp.com
About Izotropic Corporation
Izotropic Corporation is commercializing dedicated breast CT imaging technology for the earlier detection, diagnosis and treatment of breast cancers. Extensive preliminary studies have found that breast CT may be able to routinely detect small breast tumors in the 3-5 mm size range. The median size of breast cancer found using mammography is approximately 11 mm. Routine detection of 3 mm lesions would result in 1.5 year earlier detection over mammography.
The initial indication for use for breast CT as a diagnostic device has been confirmed. Forthcoming business objectives include identifying additional indications for use, development of accessories, and additional products, all aimed at making breast CT an indispensable tool for improving the outcomes of breast cancer.
Additional information about Izotropic Corporation can be found on its website at izocorp.com and by reviewing its profile on SEDAR at sedar.com
Forward Looking Statements
This document may contain statements that are “Forward-Looking Statements,” which are based upon the current estimates, assumptions, projections and expectations of the company’s management, business, and its knowledge of the relevant market and economic environment in which it operates. The Company has tried, where possible, to identify such information and statements by using words such as “anticipate,” “believe,” “envision,” “estimate,” “expect,” “intend,” “may,” “plan,” “predict,” “project,” “target,” “potential,” “will,” “would,” “could,” “should,” “continue,” “contemplate” and other similar expressions and derivations thereof in connection with any discussion of future events, trends or prospects or future operating or financial performance, although not all forward-looking statements contain these identifying words. These statements are not guarantees of performance and involve risks and uncertainties that are difficult to control or predict, and as such they may cause future results of the company’s activity to differ significantly from the content and implications of such statements. Forward-Looking Statements are pertinent only as of the date on which they are made, and the company undertakes no obligation to update or revise any Forward-Looking Statements to reflect new information or the occurrence of future events or circumstances unless otherwise required to do so by law. Neither the company nor its shareholders, officers and consultants, shall be liable for any action and the results of any action taken by any person based on the information contained herein, including without limitation the purchase or sale of company securities. Nothing in this document should be deemed to be medical or other advice of any kind.
To view the source version of this press release, please visit https://www.newsfilecorp.com/release/74914